Jeevan Scientific Technology Ltd

Operating margins swing sharply across quarters—from 27.08% (Jun 2024) to -10.08% (Mar 2025)—suggesting revenue instability or erratic cost management; verify the root cause (project mix, fixed-cost absorption, or operational issues).

Most recent quarter (Mar 2025) reported net loss of ₹1.34 Cr and negative OPM; verify whether this reflects a one-time issue or emerging structural pressure in the business.

Quarterly revenue ranges from ₹8–12 Cr across eight recent quarters with no clear uptrend; verify whether this is typical for a project-based model or flags demand or execution risk.

Zero institutional shareholding (0% FII/DII) leaves the stock reliant on promoters (30.25%) and retail investors; verify liquidity constraints and analyst coverage implications.

ROE of 23.61% demonstrates capital-efficient operations; maintaining or growing the earnings base at this return rate would drive shareholder value.

Jun 2024 achieved ₹1.6 Cr net profit on ₹12.52 Cr revenue; verify whether this profit level is repeatable and whether the company can scale operations while maintaining profitability.

Low leverage (D/E 0.25) provides financial flexibility; verify whether management plans to deploy this debt capacity to fund growth investments or acquisitions.